Scientific Industries, Inc. (SCND) is a Delaware corporation specializing in the design, manufacture, and marketing of laboratory equipment and bioprocessing systems. The company provides innovative tools for research and sample preparation, catering to universities, pharmaceutical companies, pharmacies, and other industries performing laboratory-scale research. SCND sells its products primarily through distributors, online platforms, and direct sales channels.
-
Benchtop Laboratory Equipment - Offers mixers, shakers, rotators, refrigerated and shaking incubators, magnetic stirrers, balances, scales, force gauges, automated pill counters, and moisture analyzers under the Genie™ and Torbal® divisions.
- Genie™ Division - Includes products like the Vortex-Genie® 2 Mixer, a key tool for laboratory sample preparation.
- Torbal® Division - Features pharmacy and laboratory balances, automated pill counters, and force measurement tools.
-
Bioprocessing Systems - Develops bioprocessing products with smart sensors and advanced software analytics for biomass monitoring, automated feeding, and multi-parameter sensing. Products are marketed under the DOTS brand platform.
- DOTS MPS System - Expanded into mammalian cell culture biopharma applications in 2024.
- Pipeline Products - Includes upcoming launches planned for 2025, focusing on innovative bioprocessing solutions.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Daniel Donadille Executive | Chief Executive Officer and President of the Bioprocessing Systems Operations | Daniel Donadille is the Chief Executive Officer and President of the Bioprocessing Systems Operations at SCND since the company's acquisition of Aquila. He previously served as Aquila's Chief Executive Officer, a role he held since co-founding the company in 2014. | ||
Helena R. Santos Executive | Chief Executive Officer (CEO) | Helena R. Santos serves as the Chief Executive Officer (CEO), President, and Treasurer of Scientific Industries, Inc., actively overseeing the company’s financial certifications and corporate operations. The documents do not provide details on her previous roles or start dates at SCND. | View Report → | |
Karl D. Nowosielski Executive | President of the Torbal Products Division | Karl D. Nowosielski has been with SCND since February 2014 as President of the Torbal Products Division and Director of Marketing. Previously, he served as Vice President at Fulcrum, Inc. from 2004 to February 2014. | ||
Robert P. Nichols Executive | President of the Genie Products Division of the Benchtop Laboratory Equipment operations | Robert P. Nichols has served as a key executive at SCND since February 1998, holding the role of President of the Genie Products Division of the Benchtop Laboratory Equipment operations and Corporate Secretary. He previously served as Vice President of Engineering beginning in May 2001, underscoring his long-term commitment and impact at the company. | ||
Christopher Cox Board | Class C Director | Co-Founder and Managing Partner of Population Health Partners LLC; Director at Nyrada, Inc. | Christopher Cox has been a Class C Director at SCND since February 2021. He brings extensive experience in corporate law and healthcare investment and has held leadership roles such as Executive Vice President at Medicines Company. | |
John A. Moore Board | Chairman of the Board | John A. Moore has been the Chairman of the Board at SCND since January 2020. He previously served as President and CEO of Codexis and held consulting roles, contributing to strategic leadership. | ||
John Nicols Board | Director | Chairman of Antheia, Inc.; Chairman of Solve ME/CFS Initiative | John Nicols has been a Director of SCND since March 4, 2024. He also holds external leadership roles as the Chairman of Antheia, Inc. and the Chairman of Solve ME/CFS Initiative. | |
Jurgen Schumacher Board | Director | Private investor in various startups and growth-phase technology companies; Shareholder of Science Holding GmbH | Jurgen Schumacher has been a Director at SCND since May 2021 and currently serves on the Audit Committee. He is also a private investor in various startups and a shareholder of Science Holding GmbH. | |
Michael Blechman Board | Class B Director | Consultant and Advisor at Intracoastal Strategies Group LLC | Michael Blechman has been a Class B Director at SCND since April 12, 2024. He serves on the Audit, Compensation, and Nominating Committees and brings extensive leadership experience from his previous roles at ACC, Inc.. |
- Given the turbulent macroeconomic environment and the raised $1.5 million funding, how does management plan to leverage this capital to accelerate the development and market launch of the SBI DOTS multiparameter sensor platform?
- With a reported $180,000 year-over-year revenue decline in the bioprocessing segment, what concrete measures are being taken to address financing delays and sector-specific challenges, particularly in academic and pharmaceutical markets?
- What are the commercialization timelines and risk mitigation strategies for the next-generation liquid injection system and miniaturized biomass sensor, and how will these translate into improved revenue cycles?
- Regarding your upcoming AI-enabled automated pill counting system, how does management plan to build a competitive moat around the 85% existing prescription drug data integration to capture market share in the 85,000 retail pharmacy segment?
- As the company transitions from a CapEx-heavy model to a recurring revenue model, what specific initiatives are in place to improve conversion rates amidst prolonged budget cycles and conservative capital spending by customers?
Research analysts covering Scientific Industries Inc.
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Henry Troemner, Inc. | A private label supplier to the two largest laboratory equipment distributors in the U.S. and Europe, competing in the Benchtop Laboratory Equipment market. |
IKA-Werke GmbH & Co. KG | A German company competing in the Benchtop Laboratory Equipment market. |
Benchmark Scientific, Inc. | A United States importer of China-produced products competing in the Benchtop Laboratory Equipment market. |
Heidolph Instruments GmbH | A German company competing in the Benchtop Laboratory Equipment market. |
Ohaus Corporation | An American company competing in the Torbal® brand products market. |
A&D Company Ltd. | A Japanese company competing in the Torbal® brand products market. |
Adam Equipment Co., Ltd. | A British company competing in the Torbal® brand products market. |
Avery Weigh-Tronix | An American company competing in the Torbal® brand products market. |
Capsa Healthcare | An American company competing in the VIVID® brand automated pill counters market. |
ABER Instruments | A United Kingdom-based direct competitor in the Bioprocessing Systems products market. |
PreSens GmbH | A German company that is a direct competitor in the Bioprocessing Systems products market. |
Hamilton Bonaduz AG | A Switzerland-based company that is an indirect (systemic alternatives) competitor in the Bioprocessing Systems products market. |
optek-Danulat GmbH | A German company that is an indirect (systemic alternatives) competitor in the Bioprocessing Systems products market. |
A German company that is a total solution provider and competitor in the Bioprocessing Systems products market. | |
Eppendorf SE | A German company that is a total solution provider and competitor in the Bioprocessing Systems products market. |
PyroScience GmbH | A former direct competitor in the Bioprocessing Systems products market that has entered a long-term partnership agreement with aquila. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Aquila Biolabs GmbH | 2021 | Scientific Industries acquired Aquila Biolabs GmbH by executing a Stock Purchase Agreement on April 29, 2021, for a total purchase price of approximately $7.88M, funded partly through cash and a share issuance with warrants. This strategic move adds key bioprocessing systems and associated capabilities to Scientific Industries’ portfolio and positions them to deploy a digital, sensor-based platform to address a market estimated at $1.2B annually, while also including employment agreements with key management. |
Recent press releases and 8-K filings for SCND.
- Scientific Industries Inc. reported net revenues of $2.3 million for the second quarter ended June 30, 2025, a decrease from $2.6 million in the prior year period.
- The company secured $10 million from the strategic divestiture of its Genie product line subsequent to quarter-end.
- The Torbal Division saw an 11% increase in sales year-over-year, with VIVID sales specifically up 16% year-over-year.
- Scientific Industries reported a net loss of $(1,522,700), or $(0.13) diluted earnings per share, for the three months ended June 30, 2025.
- The VIVID machine learning pill counting system is on track for commercial launch in the first quarter of 2026, and a new dissolved oxygen sensor design is expected to launch in Q4.
- Scientific Industries, Inc. (SCND) entered into an Asset Purchase Agreement on August 7, 2025, to sell substantially all assets of its Genie Division of Benchtop Laboratory Equipment to Troemner, LLC.
- The purchase price for the Genie Division assets is $9,600,000, subject to working capital adjustments, with an additional earn-out of up to $1,500,000.
- $1,140,000 of the earn-out is contingent on Scientific Industries, Inc. providing supply and transition services for the Genie products for an initial period of at least six months, renewable up to twelve months.
- Following the sale, Scientific Industries, Inc. will continue to operate its Torbal Division of Benchtop Laboratory Equipment Operations.
- Scientific Industries Inc. sold its Genie Division to Troemner, LLC, a manufacturing sister company of OHAUS Corporation, for $9.6 million in cash less working capital adjustments, plus up to $1.5 million in cash earnout over a twelve-month period.
- This divestiture is part of a strategic refocus to transform Scientific Industries into a deep-tech, AI-enabling company.
- The company will now concentrate on two core platforms: pharmacy automation with its VIVID platform and AI-enabled biomanufacturing with Scientific Bioprocessing's DOTS platform.
- Proceeds from the sale, combined with over $27 million raised since 2020, will be reinvested to accelerate the growth of the Torbal Division (VIVID) and Scientific Bioprocessing platforms.
- Scientific Industries (SCND) has invested over $31,000,000 in its scientific bioprocessing business, which currently generates about $1,700,000 in revenue, with a target of $20,000,000 in sales at a 20% EBITDA and projected breakeven before the end of 2027.
- The company reported a debt-free balance sheet with approximately $1.2 million in cash and cash equivalents as of March 31, 2025, and subsequently raised an additional $1.5 million in financing on April 18, 2025.
- Scientific Industries plans to complete its fully integrated DOTS platform in 2025 by introducing new features such as an optical pH sensor and a high-performance liquid injection system before the end of the year.
- A new sensor for baffled flasks is also expected to be introduced in the next several months, which is projected to quadruple the market opportunity for the company.